Therefore, blocking PI3K/AKT/mTOR could be an effective therapeutic strategy in AD treatment, being this pathway involved in the pathogenic mechanisms resulting in AD symptoms, as defective epidermal barrier, inflammation and allergic asthma. This evidence concerns the gene MTOR and Alzheimer disease.